Rapid non-genomic vasoconstrictor actions of aldosterone in the renal microcirculation

Journal of Steroid Biochemistry and Molecular Biology

Volumn 102, Issue 1-5 SPEC. ISS., 2006, Pages 170-174

  Arima, Shuji ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Afferent arteriole; Efferent arteriole; Glomerular capillary pressure; Mineralocorticoid receptor; Renal disease

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; ENDOTHELIUM, VASCULAR; GENOME; HUMANS; KIDNEY; MICROCIRCULATION; VASCULAR RESISTANCE; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 33751028194     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.09.018     Document Type: Article

References (38)

1. Connell J.M., and Davies E. The new biology of aldosterone. J. Endocrinol. 186 (2005) 1-20
2. Rosenberg M.E., Smith L.J., Correa-Rotter R., and Hostetter T.H. The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int. 45 (1994) 403-410
3. Remuzzi G., Ruggenenti P., and Benigni A. Understanding the nature of renal disease progression. Kidney Int. 51 (1997) 2-15
4. Ibrahim H.N., Rosenberg M.E., and Hostetter T.H. Role of renin-angiotensin-aldosterone system in the progression of renal disease: a critical review. Semin. Nephrol. 17 (1997) 431-440
5. Blasi E.R., Rocha R., Rudolph A.E., Blomme E.A., Polly M.L., and McMahon E.G. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 63 (2003) 1791-1800
6. Brown N.J. Aldosterone and end-organ damage. Curr. Opin. Nephrol. Hypertens. 14 (2005) 235-241
7. Abe K., and Ito S. The kidney and hypertension. Hypertens. Res. 20 (1997) 75-84
8. Kimura G., Uzu T., Nakamura S., Inenaga T., and Fujii H. High sodium sensitivity and glomerular hypertension/hyperfiltration in primary aldosteronism. J. Hypertens. 14 (1996) 1463-1468
9. Arima S., Kohagura K., Xu H.L., Sugawara A., Abe T., Satoh F., Takeuchi K., and Ito S. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J. Am. Soc. Nephrol. 14 (2003) 2255-2263
10. Arima S., Kohagura K., Xu H.L., Sugawara A., Uruno A., Satoh F., Takeuchi K., and Ito S. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 43 Part 2 (2004) 352-357
11. Falkenstein E., Tillmann H.C., Christ M., Feuring M., and Wehling M. Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacol. Rev. 52 (2000) 513-555
12. Wehling M., Neylon C.B., Fullerton M., Bobik A., and Funder J.W. Nongenomic effects of aldosterone on intracellular calcium in vascular smooth muscle cells. Circ. Res. 76 (1995) 973-979
13. Hayashi K., Ozawa Y., Fujiwara K., Wakino S., Kumagai H., and Saruta T. Role of actions of calcium antagonists on efferent arterioles-with special references to glomerular hypertension. Am. J. Nephrol. 23 (2003) 229-244
14. Virdis A., Neves M.F., Amiri F., Viel E., Touyz R.M., and Schiffrin E.L. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40 (2002) 504-510
15. Pu Q., Neves M.F., Virdis A., Touyz R.M., and Schiffrin E.L. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 42 (2003) 49-55
16. Nishiyama A., Yao L., Nagai Y., Miyata K., Yoshizumi M., Kagami S., Kondo S., Kiyomoto H., Shokoji T., Kimura S., Kohno M., and Abe Y. Possible contribution of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 24 (2004) 841-848
17. Arima S., Kahogura K., Abe M., and Ito S. Mechanisms that control glomerular hemodynamics. Clin. Exp. Nephrol. 5 (2001) 55-61
18. Ito S., Arima S., Ren Y., Juncos L.A., and Carretero O.A. Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J. Clin. Invest. 91 (1993) 2012-2019
19. Juncos L.A., Ito S., Carretero O.A., and Garvin J.L. Removal of endothelium dependent relaxation by antibody and complement in afferent arterioles. Hypertension 23 Suppl. I (1994) I-54-I-59
20. Imig J.D., Falck J.R., Gebremedhin D., Harder D.R., and Roman R.J. Elevated renovascular tone in young spontaneously hypertensive rats: role of cytochrome P-450. Hypertension 22 (1993) 357-364
21. Losel R.M., Feuring M., Falkenstein E., and Wehling M. Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids 67 (2002) 493-498
22. Wehling M., Spes C.H., Win N., Anson C.P., Schmidt B.M.W., Theisen S.K., and Christ M. Rapid cardiovascular action of aldosterone in man. J. Clin. Endoclinol. Metab. 83 (1998) 3517-3522
23. Schmidt B.M.W., Montealegre A., Janson C.P., Martin N., Stein-Kemmesies C., Scherhag A., Feuring M., Christ M., and Wehling M. Short term cardiovascular effects of aldosterone in healthy male volunteers. J. Clin. Endoclinol. Metab. 84 (1999) 3528-3533
24. Schmidt B.M.W., Sammer U., Fleischmann I., Schlaich M., Delles C., and Schmeider R.E. Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 47 (2006) 650-655
25. Liu S.L., Schmuck S., Chorazcyzewski J.Z., Gros R., and Feldman R.D. Aldosterone regulates vascular reactivity. Short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 108 (2003) 2400-2406
26. Uhrenholt T.R., Schjerning J., Hansen P.B., Norregaard R., Jensen B.L., Sorensen G.L., and Skøtt O. Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ. Res. 93 (2003) 1258-1266
27. Schmidt B.M.W., Oehmer S., Delles C., Bratke R., Schneider M.P., Klingbeil A., Fleischmann E.H., and Schmieder R.E. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 42 (2003) 156-160
28. Romagni P., Rossi F., Guerrini L., Quirini C., and Santiemma V. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 166 (2003) 345-349
29. Gunaruwan P., Schmitt M., Taylor J., Lee L., Struthers A., and Frennaux M. Lack of rapid aldosterone effects on forearm resistance vasculature in health. J. Renin Angiotensin Aldosterone Syst. 3 (2002) 123-125
30. Skøtt O., Uhrenholt T.R., Schjerning J., Hansen P.B., Rasmussen L.E., and Jensen B.L. Rapid actions of aldosterone in vascular health and disease-friend or foe?. Phamacol. Ther. 111 (2006) 495-507
31. Davies J.I., Band M., Morris A., and Struthers A.D. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 47 (2004) 1687-1694
32. Farquharson C.A.J., and Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppress vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101 (2000) 594-597
33. Grossmann C., Benesic A., Krug A.W., Freudinger R., Mildenberger S., Gassner B., and Gekle M. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol. Endocrinol. 19 (2005) 1697-1710
34. Haseroth K., Gerdes D., Berger S., Feuring M., Gunther A., Herbst C., Christ M., and Wehling M. Rapid nongenomic effects of aldosterone in mineralocorticoid-receptor-knockout mice. Biochem. Biophys. Res. Commun. 266 (1999) 257-261
35. Alzamora R., Michea L., and Marusic E.T. Role of 11b-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human artery. Hypertension 35 (2000) 1099-1104
36. Losel R., Schultz A., Boldyreff B., and Wehling M. Rapid effects of aldosterone on vascular cells: clinical implications. Steroids 69 (2004) 575-578
37. 2+ levels and vasoconstriction in mesenteric resistance vessels. Endocrinology 146 (2005) 973-980
38. Funder J.W. The nongenomic actions of aldosterone. Endocr. Rev. 26 (2005) 313-321